{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:55:17Z","timestamp":1759366517803,"version":"build-2065373602"},"reference-count":81,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.revmed.2023.05.013","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T07:33:23Z","timestamp":1687160003000},"page":"646-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Scl\u00e9rite et \u00e9piscl\u00e9rite"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-627X","authenticated-orcid":false,"given":"L.","family":"Perray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ungerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5114-3093","authenticated-orcid":false,"given":"T.","family":"Chazal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Br\u00e9zin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.revmed.2023.05.013_bib0410","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/art.41709","article-title":"Epidemiology of scleritis in the United Kingdom from 1997\u00a0to 2018: population-based analysis of 11\u00a0million patients and association between scleritis and infectious and immune-mediated inflammatory disease","volume":"73","author":"Braithwaite","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0415","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1097\/ICO.0b013e3182a407c3","article-title":"Incidence and prevalence of episcleritis and scleritis in Northern California","volume":"32","author":"Honik","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.revmed.2023.05.013_bib0420","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2012.08.005","article-title":"Visual outcome, treatment results, and prognostic factors in patients with scleritis","volume":"120","author":"Wieringa","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0425","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.revmed.2013.09.013","article-title":"Scl\u00e9rites, aspects cliniques, \u00e9tiologiques et th\u00e9rapeutiques\u00a0: \u00e0 propos d\u2019une s\u00e9rie de 32\u00a0observations","volume":"35","author":"Leal","year":"2014","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2023.05.013_bib0430","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ophtha.2011.07.013","article-title":"Clinical characteristics of a large cohort of patients with scleritis and episcleritis","volume":"119","author":"Sainz de la Maza","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0435","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ophtha.2003.06.006","article-title":"Evaluation of patients with scleritis for systemic disease","volume":"111","author":"Akpek","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0440","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajo.2009.07.021","article-title":"Scleritis and systemic disease association in a community-based referral practice","volume":"148","author":"Raiji","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0445","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0161-6420(94)31325-X","article-title":"Severity of scleritis and episcleritis","volume":"101","author":"Sainz de la Maza","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0450","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.survophthal.2005.04.001","article-title":"Scleritis","volume":"50","author":"Okhravi","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0455","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bjo.60.3.163","article-title":"Scleritis and episcleritis","volume":"60","author":"Watson","year":"1976","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0460","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/09273948.2015.1005240","article-title":"Posterior scleritis: analysis of epidemiology, clinical factors, and risk of recurrence in a cohort of 114\u00a0patients","volume":"24","author":"Lavric","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.05.013_bib0465","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/S0161-6420(99)90543-2","article-title":"Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients","volume":"106","author":"McCluskey","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0470","first-page":"195","article-title":"Posterior scleritis: clinical profile and imaging characteristics","volume":"46","author":"Biswas","year":"1998","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0475","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/jclinpath-2018-205360","article-title":"Histopathological evaluation of scleritis","volume":"72","author":"Hankins","year":"2019","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0480","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ajo.2007.09.024","article-title":"Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis","volume":"145","author":"Lin","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0485","first-page":"1","article-title":"Clinical relevance of autoantibodies and inflammatory parameters in non-infectious scleritis","author":"Vergouwen","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.05.013_bib0490","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/bjophthalmol-2015-307460","article-title":"Scleritis in patients with granulomatosis with polyangiitis (Wegener)","volume":"100","author":"Cocho","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0495","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/archopht.120.1.15","article-title":"Ocular characteristics and disease associations in scleritis-associated peripheral keratopathy","volume":"120","author":"Sainz de la Maza","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0500","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(91)32269-3","article-title":"Progression of scleral disease","volume":"98","author":"Tuft","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0505","first-page":"153","article-title":"Scleritis: challenges in immunopathogenesis and treatment","volume":"16","author":"Wakefield","year":"2013","journal-title":"Discov Med"},{"key":"10.1016\/j.revmed.2023.05.013_bib0510","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0161-6420(85)33822-8","article-title":"Necrotizing scleritis. A clinico-pathologic study of 41\u00a0cases","volume":"92","author":"Rao","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0515","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0161-6420(99)00719-8","article-title":"Scleritis: a clinicopathologic study of 55\u00a0cases","volume":"106","author":"Riono","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0520","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0161-6420(91)32280-2","article-title":"Immunopathology of scleritis","volume":"98","author":"Fong","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0525","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/bjo.2007.126425","article-title":"Immunopathology of necrotising scleritis","volume":"92","author":"Usui","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0530","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11926-020-0885-y","article-title":"Noninfectious autoimmune scleritis: recognition, systemic associations, and therapy","volume":"22","author":"Nevares","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.revmed.2023.05.013_bib0535","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jfo.2017.04.007","article-title":"Scleritis and episcleritis","volume":"40","author":"H\u00e9ron","year":"2017","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0540","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.revmed.2014.02.004","article-title":"Scl\u00e9rites et \u00e9piscl\u00e9rites\u00a0: prise en charge diagnostique et th\u00e9rapeutique","volume":"35","author":"H\u00e9ron","year":"2014","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2023.05.013_bib0545","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116\u00a0French patients","volume":"186","author":"Georgin-Lavialle","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0550","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1080\/09273948.2021.1942497","article-title":"Patterns of non-infectious scleritis across a tertiary eye care network using the indigenously developed electronic medical record system-eyesmart","volume":"30","author":"Murthy","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.05.013_bib0555","first-page":"393","article-title":"Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies","volume":"9","author":"Vignesh","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0560","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3899\/jrheum.190768","article-title":"Ocular manifestations in rheumatoid arthritis, connective tissue disease, and vasculitis: a systematic review and metaanalysis","volume":"48","author":"Turk","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0565","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.3390\/jcm10102118","article-title":"Rheumatoid arthritis associated episcleritis and scleritis: an update on treatment perspectives","volume":"10","author":"Promelle","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.revmed.2023.05.013_bib0570","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3899\/jrheum.170437","article-title":"Clinical correlates, outcomes, and predictors of inflammatory ocular disease associated with rheumatoid arthritis in the biologic era","volume":"45","author":"Caimmi","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0575","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10792-021-02058-8","article-title":"Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review","volume":"42","author":"Dammacco","year":"2022","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0580","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1590\/S0004-27492008000300011","article-title":"Prevalence of ocular manifestation in 198\u00a0patients with rheumatoid arthritis: a retrospective study","volume":"71","author":"Bettero","year":"2008","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0585","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5582\/irdr.2016.01014","article-title":"Granulomatosis with polyangiitis (Wegener's disease): an updated review of ocular disease manifestations","volume":"5","author":"Kubaisi","year":"2016","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.revmed.2023.05.013_bib0590","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/rheumatology\/kex261","article-title":"Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study","volume":"56","author":"Ungprasert","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2023.05.013_bib0595","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40123-019-0176-8","article-title":"Ocular manifestations of granulomatosis with polyangiitis: a review of the literature","volume":"8","author":"Sfiniadaki","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.revmed.2023.05.013_bib0600","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00296-019-04242-7","article-title":"Clinical significance of ocular manifestations in granulomatosis with polyangiitis: association with sinonasal involvement and damage","volume":"39","author":"Hinojosa-Azaola","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.revmed.2023.05.013_bib0605","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.autrev.2019.03.001","article-title":"Ocular involvement in granulomatosis with polyangiitis: a single-center cohort study on 63\u00a0patients","volume":"18","author":"P\u00e9rez-Jacoiste As\u00edn","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2023.05.013_bib0610","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000486791","article-title":"Cyclophosphamide or rituximab treatment of scleritis and uveitis for patients with granulomatosis with polyangiitis","volume":"61","author":"Ahmed","year":"2019","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.revmed.2023.05.013_bib0615","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12177-009-9044-4","article-title":"Ocular disease in patients with ANCA-positive vasculitis","volume":"3","author":"Watkins","year":"2010","journal-title":"J Ocul Biol Dis Inform"},{"key":"10.1016\/j.revmed.2023.05.013_bib0620","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/archopht.126.5.651","article-title":"Antineutrophil cytoplasmic antibody\u2013associated active scleritis","volume":"126","author":"Hoang","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0625","article-title":"ANCA-associated scleritis: impact of ANCA on presentation, response to therapy and outcome","author":"Perray","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0630","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/rheumatology\/kex057","article-title":"Ocular involvement in patients with spondyloarthritis","volume":"56","author":"Bacchiega","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2023.05.013_bib0635","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.3390\/jcm11154538","article-title":"Ocular manifestations in patients with inflammatory bowel disease in the biologics era","volume":"11","author":"Cuny","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.revmed.2023.05.013_bib0640","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.3748\/wjg.v23.i32.5836","article-title":"Ophthalmic manifestations in patients with inflammatory bowel disease: a review","volume":"23","author":"Troncoso","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0645","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/ecco-jcc\/jjv232","article-title":"Prevalence and characteristics of extra-intestinal manifestations in a large Cohort of Greek patients with inflammatory bowel disease","volume":"10","author":"Karmiris","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.revmed.2023.05.013_bib0650","doi-asserted-by":"crossref","first-page":"12264","DOI":"10.3390\/ijms232012264","article-title":"Understanding ocular findings and manifestations of systemic lupus erythematosus: update review of the literature","volume":"23","author":"Lubo\u0144","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.revmed.2023.05.013_bib0655","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/bjophthalmol-2015-306629","article-title":"Ocular manifestations in systemic lupus erythematosus","volume":"100","author":"Silpa-archa","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0660","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.3390\/jcm10214970","article-title":"Ocular involvement in relapsing polychondritis","volume":"10","author":"Fukuda","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.revmed.2023.05.013_bib0665","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/bjophthalmol-2015-306902","article-title":"Scleritis associated with relapsing polychondritis","volume":"100","author":"Sainz-de-la-Maza","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0670","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2012.01.033","article-title":"Clinical features and presentation of infectious scleritis from herpes viruses: a report of 35\u00a0cases","volume":"119","author":"Gonzalez-Gonzalez","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0675","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S0161-6420(91)32062-1","article-title":"Necrotizing scleritis after ocular surgery. A clinicopathologic study","volume":"98","author":"Sainz de la Maza","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0680","doi-asserted-by":"crossref","first-page":"E431","DOI":"10.1503\/cmaj.111752","article-title":"Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study","volume":"184","author":"Etminan","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.revmed.2023.05.013_bib0685","doi-asserted-by":"crossref","first-page":"98","DOI":"10.36401\/JIPO-22-14","article-title":"Highlights on ocular toxicity of immune checkpoint inhibitors at a US Tertiary Cancer Center","volume":"5","author":"Mazharuddin","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0690","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10384-019-00674-7","article-title":"Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases (anti-neutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis)","volume":"63","author":"Yoshida","year":"2019","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0695","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.semarthrit.2012.08.003","article-title":"Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286\u00a0patients and review of the literature","volume":"42","author":"Rothschild","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2023.05.013_bib0700","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/09286580701585892","article-title":"Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the systemic immunosuppressive therapy for eye diseases (SITE) cohort study","volume":"15","author":"Kempen","year":"2008","journal-title":"Ophthal Epidemiol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0705","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0710","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0715","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0720","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":"Cyclophosphamide for ocular inflammatory diseases","volume":"117","author":"Pujari","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0725","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"Ka\u00e7maz","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0730","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/bjophthalmol-2015-307462","article-title":"Efficacy and safety of immunosuppressive agents in the treatment of necrotising scleritis: a retrospective, multicentre study in Korea","volume":"100","author":"Jeon","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0735","first-page":"1138","article-title":"Effectiveness of TNF-\u03b1 blockade in the treatment of refractory non-infectious scleritis: a multicentre study","volume":"38","author":"Fabiani","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0755","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10792-015-0124-0","article-title":"Biologic therapy for refractory scleritis: a new treatment perspective","volume":"35","author":"de Fidelix de","year":"2015","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0740","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3899\/jrheum.110865","article-title":"Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease","volume":"39","author":"Gaujoux-Viala","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0745","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0750","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12348-021-00252-4","article-title":"Rituximab for non-infectious uveitis and scleritis","volume":"11","author":"Ng","year":"2021","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.revmed.2023.05.013_bib0760","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: results of a phase I\/II dose-ranging, randomized, clinical trial","volume":"121","author":"Suhler","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0765","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1080\/09273948.2017.1327602","article-title":"Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener's)","volume":"26","author":"You","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.05.013_bib0770","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ophtha.2015.01.016","article-title":"Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: impact on localized and nonlocalized disease","volume":"122","author":"Joshi","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0775","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/09273948.2017.1299869","article-title":"Anakinra in the treatment of patients with refractory scleritis: a pilot study","volume":"26","author":"Bottin","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.05.013_bib0780","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajo.2016.09.017","article-title":"Gevokizumab in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I\/II clinical trial","volume":"172","author":"Knickelbein","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0785","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1111\/aos.13015","article-title":"Outcome of tocilizumab treatment in refractory ocular inflammatory diseases","volume":"94","author":"Silpa-Archa","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0790","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09273948.2020.1763405","article-title":"Sustained remission with tocilizumab in refractory relapsing polychondritis with ocular involvement: a case series","volume":"29","author":"Farhat","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2023.05.013_bib0795","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.revmed.2023.05.013_bib0800","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/bjo.2009.164962","article-title":"Subconjunctival triamcinolone treatment for non-necrotising anterior scleritis","volume":"94","author":"Roufas","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2023.05.013_bib0805","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.ophtha.2011.02.043","article-title":"Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis","volume":"118","author":"Sohn","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2023.05.013_bib0405","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/ICL.0000000000000696","article-title":"Experience with 0.1\u00a0% tacrolimus eye drop for noninfectious, non-necrotizing anterior scleritis","volume":"47","author":"Yazu","year":"2021","journal-title":"Eye Contact Lens"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886632300646X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886632300646X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:47:02Z","timestamp":1759337222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024886632300646X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S024886632300646X"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2023.05.013","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scl\u00e9rite et \u00e9piscl\u00e9rite","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2023.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}